From: Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency
Annualized change in measurements over study period | ||
---|---|---|
Mean (95% CI)* | P-value* | |
Spirometry† | ||
FEV1, ml | -36 (-67 to -5) | 0.025 |
FVC, ml | -6 (-113 to +102) | 0.92 |
FEV1/FVC ratio | -1% (-2% to -0.02%) | 0.046 |
Total Lung Capacity, ml† | -48 (-152 to +56) | 0.36 |
Transfer Factor (TLco), mmol/min/kpa† | -0.2 (-0.34 to -0.08) | 0.002 |
CT Densitometry | ||
Adjusted Lung Density‡ | -1.8 (-2.4 to -1.1) | <0.001 |
Resting Oxygenation Saturation (room air) | 0.2% (-0.3% to +0.6%) | 0.43 |
Incremental Shuttle Walk Test | ||
Distance Walked, meters | -8 (-23 to +6) | 0.26 |